ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi) to silence specific genes associated with disease. The company has no commercial manufacturing capabilities and relies on strategic alliances and government contracts for funding. As of February 29, 2008, the company had 129 employees, with 102 engaged in research and development.

Key Financial Metrics

Note: The company has not generated revenue from product sales. Revenues are derived from collaboration agreements, government contracts, and licensing.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 89% to $50.9 million, primarily driven by a new strategic alliance with Roche announced in August 2007. Roche contributed $17.6 million in recognized revenue for 2007.
• Expense Surge: Operating expenses increased 117% to $144.1 million. R&D expenses rose 145% to $120.7 million. This increase was largely due to $27.5 million in license fees paid to licensors (primarily Isis Pharmaceuticals) triggered by the Roche alliance, and $14.7 million in charges for delivery technology licenses.
• Liquidity Improvement: Cash and marketable securities more than doubled to $455.6 million, fueled by $331.0 million in upfront payments received from the Roche alliance (comprising $273.5 million cash, $42.5 million stock purchase, and $15.0 million asset sale).
• Deferred Revenue: Total deferred revenue increased significantly to $263.3 million, reflecting the large upfront payments from Roche that will be recognized over five years.

Guidance, Outlook, and Risks

Management Commentary and Outlook

Management expects to continue incurring net operating losses for the foreseeable future as it advances its product pipeline. The company anticipates that existing resources, combined with cash generated from current alliances (specifically Roche), will fund operations for at least the next several years. No specific financial guidance for future periods was provided in the text.

Key Developments

• Roche Alliance: A broad, non-exclusive platform license and collaboration agreement providing significant upfront funding and future milestone/royalty potential.
• Regulus Therapeutics: Established a joint venture with Isis Pharmaceuticals in September 2007 to develop microRNA (miRNA) therapeutics. Alnylam holds a 49% interest.
• Clinical Progress: Reported positive Phase II results (GEMINI study) for ALN-RSV01 (RSV treatment) in February 2008, showing a 40% reduction in viral infection. Plans to initiate a second Phase II trial in naturally infected patients in the first half of 2008.

Risks and Contingencies

• Profitability: The company has a history of losses and may never achieve profitability. It relies heavily on external funding.
• Technology Risk: RNAi is an unproven therapeutic approach; no RNAi drugs have received regulatory approval. Challenges remain in delivery and potential off-target effects.
• Collaboration Dependence: Significant reliance on partners like Roche and Novartis for funding and commercialization. Termination of these agreements would materially harm the business.
• Intellectual Property: The company faces potential patent litigation and opposition proceedings (e.g., regarding the Kreutzer-Limmer and Glover patents) which could invalidate key IP rights.

Investor Verification Checklist

• Roche Revenue Recognition: Verify the five-year straight-line amortization schedule for the $278.2 million deferred revenue from Roche and the assumptions regarding performance obligations.
• R&D Burn Rate: Assess the sustainability of the $120.7 million R&D spend, noting that a significant portion ($42.2 million) was one-time license fees. Determine the run-rate excluding these non-recurring costs.
• Cash Runway: Confirm the timeline for the $455.6 million cash balance to support operations given the high burn rate and lack of product sales revenue.
• Patent Status: Review the status of opposition proceedings against key patents (Kreutzer-Limmer, Glover) and the potential impact on the company's freedom to operate.
• Regulus JV: Evaluate the financial health and progress of the Regulus Therapeutics joint venture, as Alnylam is responsible for funding the first $10 million of losses.